Startups

May Health

Paris, France · Menlo Park, California, United States

May Health develops the Anavi System, a medical device intended to restore natural ovulation in women with infertility associated with polycystic ovary syndrome (PCOS). The one-time, ultrasound-guided procedure uses radiofrequency energy to ablate targeted ovarian tissue, aiming to reduce ovarian androgen production. It is being evaluated for women who do not respond to, cannot use, or decline first-line ovulation-induction therapies. The system received European CE certification under the EU Medical Device Regulation in October 2025. In the United States it remains investigational: the company is enrolling its randomized REBALANCE pivotal IDE trial to support a future application for FDA marketing authorization. European commercialization is being planned; CE certification does not establish US marketing approval. The company evolved through Sofinnova MD Start, previously operated as Ablacare, and has teams in Paris and Menlo Park.

Founded 2017

Team

Andrew M. WeissDirector and Venture Advisor

Anne BubbVice President, Marketing

Anne OsdoitDirector

Antoine PapiernikDirector

Aruna AkkapeddiVice President, Quality Assurance/Regulatory Affairs

Bita SehatDirector

Cindy DomecusChief Regulatory Advisor

Colby HoltshousePresident, Chief Executive Officer and Director

Connie ReyVice President, Clinical Affairs

Hugh E. MagenChief Technical Officer

Jean-François MorinDirector

Matt FranklinActing Chief Financial Officer

Robert AuerbachBoard Chair

Ross W. McQuiveyChief Medical Advisor

Investments

€10M2026-03-10	Sofinnova Partners, Trill Impact, Bpifrance
$25M2024-05-13	Bpifrance, Trill Impact, Sofinnova Partners, Kidron Capital, Avestria Ventures

team@apexlogos.ai16 hours ago
Financing precision: March 10, 2026 issuer announced EUR10m ($11.7m conversion), with current investors including Sofinnova Partners, Trill Impact and Bpifrance, plus new investor Nexpring Health. Native round amount is EUR10m; USD11.7m is a conversion of that same financing, not additional capital. Primary issuer does not state a financing stage, exact individual tickets or round co-leads. Kidron is not named in this round and is not assigned to it. Nexpring is a corporate ART-solutions company queued for full profiling before an investor link; not assumed a venture fund. No holdings are allocated to a particular manager fund.
team@apexlogos.ai16 hours ago
Financing precision: May 13, 2024 issuer announcement confirms a closed USD25m Series B co-led by Bpifrance and Trill Impact, with Sofinnova Partners, Avestria Ventures and Kidron Capital Assets LP participating. Native Kidron Capital investor10876 is the women’s-health manager identity already verified through its own issuer/domain evidence; no fund allocation or personal managing-partner check inferred. Avestria is queued for a complete manager profile before creating an investor. Individual tickets are undisclosed.
team@apexlogos.ai16 hours ago
Identity and status: own company history names Ziva Medical, integration into MD Start and the Ablacare SAS / May Health SAS / May Health Inc. renaming sequence. This company-level operating profile does not purport to merge distinct legal entities. Foundation in 2017 is issuer-confirmed for the MD Start company; no predecessor incorporation date inferred. CE certification occurred in October 2025 and was publicly announced December 16, 2025. Anavi remains investigational in the US; FDA IDE authorization is permission for the clinical study, not product marketing approval.